1-Azabicyclo[2.2.1]heptan-4-amine dihydrochloride | 1338705-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-Azabicyclo[2.2.1]heptan-4-amine dihydrochloride
• 英文别名: 1-azabicyclo[2.2.1]heptan-4-amine;dihydrochloride
• CAS: 1338705-69-3
• 化学式: C6H14Cl2N2
• 分子量: 185.09
• InChiKey: MQAPWAQFEMCHRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.64
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• [EN] 4—(1H— IMIDAZOL— 5— YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS<br/>[FR] 4-(1H-IMIDAZOL-5-YL)-1H-PYRROLO [2,3-B] PYRIDINES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DE LEUCÉMIES, DE LYMPHOMES ET DE TUMEURS SOLIDES
  申请人：UNIV MASARYKOVA

  公开号：WO2019185631A1

  公开（公告）日：2019-10-03

  The present invention relates to novel 4-(1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridine compounds which are useful in the treatment of lymphomas, leukaemias, and solid tumors.

  本发明涉及一种新型的4-(1H-咪唑-5-基)-1H-吡咯[2,3-b]吡啶化合物，可用于治疗淋巴瘤、白血病和实体肿瘤。
• 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors
  申请人：MASARYKOVA UNIVERZITA

  公开号：US11498920B2

  公开（公告）日：2022-11-15

  Novel 4-(1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridine compounds that are useful in the treatment of lymphomas, leukaemias, and solid tumors.

  可用于治疗淋巴瘤、白血病和实体瘤的新型 4-(1H-咪唑-5-基)-1H-吡咯并[2,3-b]吡啶化合物。
• 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS
  申请人：Masarykova Univerzita

  公开号：EP3774795A1

  公开（公告）日：2021-02-17
• 3-(5-AMINO-PYRAZIN-2-YL)-BENZENESULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PI3K-GAMMA KINASE INHIBITORS FOR TREATING E.G. CANCER
  申请人：Incyte Corporation

  公开号：US20200331903A1

  公开（公告）日：2020-10-22

  This application relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.